Skip to main content
MDRSF logo

Medartis Holding AG (MDRSF) Stock Price & Analysis

Medartis Holding AG (MDRSF) — price $115.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.43B.

Educational signal · not a buy or sell recommendation · How to read this

$115.00 $0.00 (0.00%) Market Cap $1.43B

Medartis Holding AG · MDRSF

Medartis Holding AG is a Switzerland-based medical technology firm specializing in advanced implant solutions for bone fracture repair in limbs and cranio-maxillofacial regions. Operating under APTUS and MODUS brands, the company globally develops, manufactures, and distributes specialized osteosynthesis instruments to healthcare providers.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • PRCT · PROCEPT BioRobotics Corporation · 32 /100
  • CNMD · CONMED Corporation · 79 /100
  • LMRI · Lumexa Imaging Holdings, Inc. Common Stock · 33 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$115.00
Change on the day0.00%
Market capitalisation$1.43B
Price / earnings (trailing)93.00
Shares traded on the day217

Price & events

Other perspectives

Council score for Medartis Holding AG (MDRSF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 1, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Overvalued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Weak
ROE Weak
Gross Margin Strong

Read on: Sep 1, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 1, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Medartis Holding AG (MDRSF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Medartis Holding AG (MDRSF) is the company analyzed here. It employs 1,428 people. In Q2 FY2026 it reported revenue of CHF 160M and net income of CHF 5M. The market values it at $1.43B.

2 · Latest results

What do the latest results show for Medartis Holding AG (MDRSF)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CHF 160M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CHF 160MCHF 5MCHF 0.41 (diluted)
Q4 FY2025CHF 146MCHF 10MCHF 0.79 (diluted)
Q2 FY2025CHF 123M-CHF 1M-CHF 0.12 (diluted)
Q4 FY2024CHF 113MCHF 963,000CHF 0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Medartis Holding AG (MDRSF)?

Short answer · as of

The distress and quality screens read Altman Z 3.02 · Piotroski F 6. Trailing ratios: ROE 5.4% · ROA 2.4% · current ratio 3.36 · earnings yield 1.1% · free-cash-flow yield 0.1%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MDRSF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MDRSF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About MDRSF

These answers are editorial: 1 of these 8 answers is drawn from the MDRSF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is MDRSF a good stock to buy?

Stock Expert AI does not rate MDRSF buy, sell or hold. Medartis Holding AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MDRSF stock price today?

The last price recorded for Medartis Holding AG (MDRSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks associated with investing in MDRSF, particularly given its OTC listing?

Investing in Medartis Holding AG, especially as an OTC Other listed stock, involves several notable risks. A primary concern is the inherent liquidity risk associated with OTC Other securities, which typically exhibit lower trading volumes and wider bid-ask spreads compared to major exchange-listed stocks. This can make it challenging to execute trades efficiently.

What are the key factors to evaluate for MDRSF?

Evaluate MDRSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. New Product Development and Innovation: Continuous investment in research and development to introduce new, more advanced, or minimally invasive implant solutions represents a key growth driver. Not financial advice.

How frequently does MDRSF data refresh on this page?

MDRSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MDRSF's recent stock price performance?

Medartis Holding AG (MDRSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in high-precision surgical fixation implants for extremities and cranio-maxillofacial regions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MDRSF overvalued or undervalued right now?

The trailing P/E of Medartis Holding AG (MDRSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MDRSF before investing?

Before investing in Medartis Holding AG (MDRSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 10 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.